Gene: SLC17A6

57084
DNPI|VGLUT2
solute carrier family 17 member 6
protein-coding
11p14.3
Ensembl:ENSG00000091664 MIM:607563 Vega:OTTHUMG00000166063 UniprotKB:Q9P2U8
NC_000011.10
PubMed
0   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.453e-1 (AD)  2.094e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FAM19A20.844
CBLN40.841
MCF20.841
SNX100.837
SCN1A0.836
RET0.834
XK0.831
ARL60.83
CACNA2D10.829
PTH2R0.828

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
REST-0.495
CSAG1-0.492
RAI14-0.486
CNN2-0.474
FZD10-0.472
CHD7-0.468
CPM-0.464
CDCA7L-0.455
HEY2-0.454
SYDE1-0.453

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC17A6 mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of SLC17A6 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC17A6 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC17A6 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC17A6 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC17A6 mRNA"25510870
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of SLC17A6 gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of SLC17A6 mRNA16483693
C015001arsenitearsenite results in increased methylation of SLC17A6 promoter23974009
D001280AtrazineAtrazine results in decreased expression of SLC17A6 mRNA25929836
D019324beta-Naphthoflavone[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of SLC17A6 mRNA18164116
D004958Estradiol[Estradiol co-treated with Progesterone] results in increased expression of SLC17A6 mRNA22154832
D004958EstradiolEstradiol results in increased expression of SLC17A6 mRNA22154832
C006780bisphenol Abisphenol A results in decreased expression of SLC17A6 mRNA25181051
D003024ClozapineClozapine results in increased expression of SLC17A6 mRNA17266109|1815507
D003024ClozapineClozapine results in increased expression of SLC17A6 protein18155072
D003042CocaineCocaine results in increased expression of SLC17A6 protein25100957
D003561CytarabineCytarabine results in increased expression of SLC17A6 mRNA21198554
D013759DronabinolDronabinol results in decreased expression of SLC17A6 mRNA21955143
D004008DiclofenacDiclofenac results in increased expression of SLC17A6 mRNA26934552
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of SLC17A6 mRNA18164116
C118739entinostatentinostat results in decreased expression of SLC17A6 mRNA27188386
D000431EthanolEthanol results in increased expression of SLC17A6 mRNA21955143
D000431EthanolEthanol results in decreased expression of SLC17A6 mRNA20655511
C069837fullerene C60fullerene C60 results in decreased expression of SLC17A6 mRNA19167457
C039281furanfuran results in decreased expression of SLC17A6 mRNA25539665
C004312glycidolglycidol results in decreased expression of SLC17A6 mRNA24915197
D006220HaloperidolHaloperidol results in increased expression of SLC17A6 mRNA18155072
D006220HaloperidolHaloperidol results in increased expression of SLC17A6 protein18155072
D007657Ketone BodiesKetone Bodies results in decreased expression of SLC17A6 mRNA16807920
C008261lead acetatelead acetate results in decreased expression of SLC17A6 mRNA22613225
D008094LithiumLithium results in increased expression of SLC17A6 mRNA18155072
D008094LithiumLithium results in increased expression of SLC17A6 protein18155072
D008727MethotrexateMethotrexate affects the expression of SLC17A6 mRNA18502557
D008731MethoxychlorMethoxychlor results in increased expression of SLC17A6 mRNA22016562
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of SLC17A6 mRNA23203475
D009020MorphineMorphine results in decreased expression of SLC17A6 mRNA21955143
C028007nickel monoxidenickel monoxide results in decreased expression of SLC17A6 mRNA19167457
D009538NicotineNicotine results in decreased expression of SLC17A6 mRNA21955143
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC17A6 mRNA"25510870
D010622PhencyclidinePhencyclidine results in increased expression of SLC17A6 mRNA17266109
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of SLC17A6 mRNA19710929
D059808PolyphenolsPolyphenols results in decreased expression of SLC17A6 mRNA16293270
D011374Progesterone[Estradiol co-treated with Progesterone] results in increased expression of SLC17A6 mRNA22154832
D018967RisperidoneRisperidone results in increased expression of SLC17A6 mRNA18155072
D018967RisperidoneRisperidone results in increased expression of SLC17A6 protein18155072
C009250sevofluranesevoflurane affects the expression of SLC17A6 mRNA15967596
C017947sodium arsenitesodium arsenite affects the methylation of SLC17A6 gene28589171
D013605T-2 ToxinT-2 Toxin results in decreased expression of SLC17A6 mRNA26314264
D014050TolueneToluene results in increased expression of SLC17A6 mRNA22967744
D014635Valproic AcidValproic Acid affects the expression of SLC17A6 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased methylation of SLC17A6 gene29154799
D014635Valproic AcidValproic Acid results in decreased expression of SLC17A6 protein16169023
D014635Valproic AcidValproic Acid affects the expression of SLC17A6 mRNA17963808
D014635Valproic AcidValproic Acid results in decreased expression of SLC17A6 mRNA24896083
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of SLC17A6 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005313L-glutamate transmembrane transporter activity-IBA21873635  
GO:0005313L-glutamate transmembrane transporter activity-TAS-  
GO:0005326neurotransmitter transporter activity-IBA21873635  
GO:0015293symporter activity-IEA-  
GO:0022857transmembrane transporter activity-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0006811ion transport-TAS-  
GO:0006814sodium ion transport-IEA-  
GO:0006820anion transport-IBA21873635  
GO:0015813L-glutamate transmembrane transport-IEA-  
GO:0035249synaptic transmission, glutamatergic-IBA21873635  
GO:0050803regulation of synapse structure or activity-IBA21873635  
GO:0098700neurotransmitter loading into synaptic vesicle-IBA21873635  
GO:0098700neurotransmitter loading into synaptic vesicle-IMP11698620  
GO ID GO Term Qualifier Evidence PubMed
GO:0016021integral component of membrane-IBA21873635  
GO:0030054cell junction-IEA-  
GO:0030285integral component of synaptic vesicle membrane-IBA21873635  
GO:0030672synaptic vesicle membrane-IBA21873635  
GO:0030672synaptic vesicle membrane-TAS-  
GO:0043005neuron projection-IEA-  
GO:0060076excitatory synapse-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-382551Transport of small moleculesTAS
R-HSA-425393Transport of inorganic cations/anions and amino acids/oligopeptidesTAS
R-HSA-425407SLC-mediated transmembrane transportTAS
R-HSA-428643Organic anion transportersTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
17928304Smoking and alcoholism target genes associated with plasticity and glutamate transmission in the human ventral tegmental area. (2008 Jan 1)Flatscher-Bader THum Mol Genet
29352099Smoking and Parkinson disease: Evidence for gene-by-smoking interactions. (2018 Feb 13)Lee PCNeurology